New Heart Failure Data Have Been Reported by Investigators at Department of Cardiovascular Medicine (Comparative Renoprotection: Sacubitril/valsartan Versus Acei or Arb - a Systematic Review and Meta-analysis).

A recent systematic review and meta-analysis conducted in Chongqing, People's Republic of China, compared the renoprotective effects of sacubitril/valsartan (Sac/Val) with angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB) in patients with heart failure. The study found that Sac/Val significantly reduced the risk of renal function decline compared to ACEI/ARB, particularly in patients with heart failure. However, further research is needed to fully understand the potential of Sac/Val as a nephroprotective agent. This research provides valuable insights into the comparative effectiveness of different medications for heart failure patients. [Extracted from the article]